The Group is focused on delivering to shareholders, over the medium to longer term, value growth and profitability through commercialisation of its intellectual property.
The Directors believe that the Affimer affinity reagent platform provides the greatest potential for such value growth by delivering a profitable research reagents business alongside therapeutic Affimer partnerships and an in-house therapeutic development pipeline. The Group is therefore focusing its investments primarily its proprietary Affimer technology.
Country of Registration & Operation
The Company is Registered in England and Wales (Registration number 04748597) and the main country of operation is the UK.
Registered office – Unit 20, Ash Way, Thorp Arch Estate, Wetherby LS23 7FA.
Current significant shareholders are as follows:
IP Group plc – 24.8%
Henderson Global Investors – 11.5%
Baillie Gifford & Co Limited – 7.2%
Ruffer LLP – 7.1%
Fidelity - 5.8%
J O Hambro - 5.7%
NFU - 3.5%
As at 25th May 2017 the company has 68,392,588 ordinary shares of 10p each in issue.
42.3% of the ordinary shares of the Company are not held in public hands.
Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
There are no restrictions on the transfer of Avacta Group plc’s AIM securities.
Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.
This information was last updated on 25th May 2017.
Joint broker and Nomad – finnCap Limited, 60 New Broad Street, London EC2M 1JJ
Joint broker – WG Partners, 85 Gresham Street, London, EC2V 7NQ
Auditor – KPMG LLP, 1 Sovereign Square, Sovereign Street, Leeds, LS1 4DA
Solicitor – Walker Morris, Kings Court, 12 King Street, Leeds, LS1 2HL
Registrar – Capita IRG plc, Bourne House, 34 Beckenham Road, Beckenham, BR3 4TU. www.capitashareportal.com
Investor and Media Relations – FTI Consulting, 200 Aldersgate, London, EC1A 4HD, +44 (0)20 3727 1000, email@example.com / firstname.lastname@example.org.